Cover Image
Market Research Report

Global Soft Tissue Sarcoma Market 2019-2026

Published by DataM Intelligence Product code 757930
Published Content info
Delivery time: 1-2 business days
Back to Top
Global Soft Tissue Sarcoma Market 2019-2026
Published: December 1, 2019 Content info:

Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues.

There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcoma such as sunitinib (sutent), trabectedin (yondelis), sirolimus (rapamune), bevacizumab (avastin), doxorubicin (adriamycin), and others.

In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company's drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.

Clinical Trial Analysis:

Total Soft Tissue Sarcoma Studies: 1567

By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs and Others. Chemotherapy has the largest market share in soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.

Regional Insights:

Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.

The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.

Some recent approved drugs for the treatment of Soft Tissue Sarcoma are:

  • In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX™ liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Target Audience

  • Raw Material Suppliers/ Buyers
  • Product Suppliers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Why purchase the report?

  • Visualize the composition of the Global Soft Tissue Sarcoma market across each indication, in terms of type and applications, highlighting the key commercial assets and players.
  • Identify commercial opportunities in Global Soft Tissue Sarcoma by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Global Soft Tissue Sarcoma market - level 4/5 segmentation
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
  • Product mapping in excel for the key Global Soft Tissue Sarcoma products of all major market players
Table of Contents

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Research methodology
  • 1.2 Scope of the Report

Chapter 2. Executive Summary

Chapter 3. Industry Analysis

  • 3.1 Market Drivers
  • 3.2 Market Restraints
  • 3.3 Porters Five Forces Analysis
    • 3.3.1 Suppliers Power
    • 3.3.2 Buyer Power
    • 3.3.3 Industry Competition
    • 3.3.4 Threat of new Entrant
    • 3.3.5 Threat of Substitutes

Chapter 4. Global Soft Tissue Sarcoma Market - Epidemiology

Chapter 5. Global Soft Tissue Sarcoma Market -Product Pipeline Analysis

Chapter 6. Global Soft Tissue Sarcoma Market -Clinical Trail Analysis

Chapter 7. Segmentation by Disease Type

  • 7.1 Local sarcoma
  • 7.2 Regional sarcoma
  • 7.3 Metastatic sarcoma

Chapter 8. Segmentation by Treatment

  • 8.1 Radiation Therapy
  • 8.2 Chemotherapy
  • 8.3 Targeted therapy
  • 8.4 Anti-angiogenesis drugs
  • 8.5 Other Treatments

Chapter 9. Segmentation by End-User

  • 8.1 Hospitals
  • 8.2 Oncology Centers
  • 8.3 Others

Chapter 10. Geographical Analysis

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
    • 10.1.4 Others
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Spain
    • 10.2.3 Germany
    • 10.2.4 France
    • 10.2.5 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 India
    • 10.3.2 China
    • 10.3.3 Australia
    • 10.3.4 Japan
    • 10.3.5 Rest of Asia-Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Rest of South America
  • 10.5 Rest of the World

Chapter 11. Competitive Landscape

  • 11.1 Market Share Analysis
  • 11.2 Company Benchmarking
  • 11.3 Key Strategies Adopted by Major Companies

Chapter 12 Company Profiles*

  • 12.1 F. Hoffmann-La Roche Ltd.
  • 12.2 GlaxoSmithKline Plc
  • 12.3 Pfizer, Inc.
  • 12.4 Johnson & Johnson Services, Inc.
  • 12.5 Teva Pharmaceutical Industries Ltd.
  • 12.6 Celgene Corporation
  • 12.7 Bristol-Myers Squibb Company
  • 12.8 Threshold Pharmaceuticals Inc.
  • 12.9 Merck KGaA.

Chapter 12 Appendix

  • 12.1 Sources
  • 12.2 List of Tables
  • 12.3 Expert Panel Validation
  • 12.4 Disclaimer
  • 12.5 Contact Us
  • Note: Additional company profiles will be included on request
Back to Top